A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in
progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic
signature or BRCA 1 or 2 somatic mutation, without known BRCA 1 or 2 germline mutation.